Disc Medicine Inc. (IRON)
Disc Medicine Inc. (IRON) Stock Price, Analysis & Data
| Bid | 56.05 |
| Market Cap | 3.03B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -245.89M |
| Beta | 2.06 |
| EPS (ttm) | -6.59 |
| PE Ratio (ttm) | n/a |
| Forward PE | -10.85 |
| P/B (ttm) | 4.69 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 77.67 |
| Volume | 245,976 |
| Avg. Volume (20D) | 527,925 |
| Open | 79.53 |
| Previous Close | 80.01 |
| Day's Range | 77.99 - 80.65 |
| 52-Week Range | 40.00 - 99.50 |
| Analyst | Strong Buy |
| Price Target | 100 (26.84%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood c...
Financial Performance
In 2025, Disc Medicine's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -212.18M, an increase of 94.03%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for IRON stock is "Strong Buy". The 12-month stock price forecast is 100, which is upside of 26.84% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
